Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
, 10 (6), 316

Drotrecogin Alfa (Activated) Should Not Be Used in Patients With Severe Sepsis and Low Risk for Death

Affiliations
Comment

Drotrecogin Alfa (Activated) Should Not Be Used in Patients With Severe Sepsis and Low Risk for Death

Sanjay Gupta et al. Crit Care.

Comment on

Similar articles

See all similar articles

Cited by 2 PubMed Central articles

References

    1. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005;353:1332–1341. doi: 10.1056/NEJMoa050935. - DOI - PubMed
    1. Dhainaut JF, Yan SB, Margolis BD, Lorente JA, Russell JA, Freebairn RC, Spapen HD, Riess H, Basson B, Johnson G, III, Kinasewitz GT. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost. 2003;90:642–653. - PubMed
    1. Siegel JP. Assessing the use of activated protein C in the treatment of severe sepsis. N Engl J Med. 2002;347:1030–1034. doi: 10.1056/NEJMsb021512. - DOI - PubMed
    1. Baillie JK, Murray G. Drotrecogin alfa (activated) in severe sepsis. N Engl J Med. 2006;354:94–96. doi: 10.1056/NEJMc052759. - DOI - PubMed
    1. Friedrich JO. Drotrecogin alfa (activated) in severe sepsis. N Engl J Med. 2006;354:94–96. doi: 10.1056/NEJMc052759. - DOI - PubMed

LinkOut - more resources

Feedback